Companion Diagnostics Markets with COVID-19 Impacts by Funding Source and Application with Customised Forecasting, Analysis, Executive and Consultant Guides 2021 to 2025
November 2020 edition
Companion Diagnostics (CDx) are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immuno-oncology is leading the way and the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing.
Will Personalized Companion Diagnostics become the norm?
Learn how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities, with some players already taking the lead. A dynamic market situation with enormous opportunity, diagnostic companies are trying to back the right horse. The science is racing forward and the cost of molecular diagnostics continues to fall.
Use this new report to forecast demand for new testing regimes and/or technologies and make confident research investment decisions. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.
The report includes detailed breakouts for 18 countries and 4 regions. A detailed breakout for any country or specific area in the world is available to purchasers of the report.
Subscribe and Save
By signing up for the annual subscription, updates to this report will be automatically provided free of charge for a period of one year from initial purchase. These updates can include revised forecasts as markets increase or contract and exclusive market commentary not seen anywhere else. With the effects of COVID-19 being felt across all markets it has never been more crucial to stay fully informed with real-world actionable data. Subscribe to this report and receive ongoing market forecasting and analysis for sharpened strategic planning throughout the year.
- Quarterly report updates
- Summary of significant developments and market changes
- Phone consultation and assistance on request for the duration of the subscription
Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Check all your licensing options, however your order is available as a credit if you wish to upgrade. We wrote this report and are ready by phone or email to help you use it.
All report data is available in Excel format on request with the corporate license.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School